亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Use of Pyroglutamyl-Glutamyl-Prolyl Amide (Eep) for Neurological and Neurobehavioral Disorders

*Abstract: A tri-peptide drug for treatment of neurological and neurobehavioral disorders of a mammal, such drug being derived from the following formula: pGlu-X-Pro-NH 2 , wherein the internal amino acid (X) is a non-histadine amino acid. Methods of treatment of neurological disorders using the tri-peptide, including as an adjunct, synergist or stand-alone therapy, in oral, parenteral, intranasal, transcutaneous, or rectal forms.

*Principal Investigation: Name: Robert Lloyd
Department:

Name: Albert Pekary
Department:

Name: Albert Pekary
Department:

Name: Albert Sattin
Department:

Name: Albert Sattin
Department:

附加資料: Patent Number: US6475989B1
Application Number: US1998169657A
Inventor: Sattin, Albert | Pekary, Albert E. | Lloyd, Robert L.
Priority Date: 9 Oct 1997
Priority Number: US6475989B1
Application Date: 9 Oct 1998
Publication Date: 5 Nov 2002
IPC Current: A61K003806 | C07K0005097 | A61K003800
US Class: 5140175 | 514018 | 530331
Title: Use of pyroglutamyl-glutamyl-prolyl amide (EEP) for neurological and neurobehavioral disorders
Usefulness: Use of pyroglutamyl-glutamyl-prolyl amide (EEP) for neurological and neurobehavioral disorders
Summary: For the treatment of depression, schizophrenia and affective disorders (claimed) e.g. anxiety and mood disorders. Also useful for the treatment of neuromuscular weakness, spinal cord trauma, spasticity, dementia, Alzheimer's disease, somatization disorders, psychosomatic disorders, functional bowel disorders, epileptic disorders, sleep disorders and loss of motoric or cognitive functions resulting from spinal cord or brain stem injuries.
Novelty: Treatment of neurological and neurobehavioral disorders e.g. depression involves use of a composition comprising a tri-peptide or its salt

欲了解更多信息，請點擊這裡